INCY 25 (Jakafi 25 mg)
Generic Name: ruxolitinib
Pill with imprint INCY 25 is White, Elliptical / Oval and has been identified as Jakafi 25 mg. It is supplied by Incyte Corporation.
Jakafi is used in the treatment of myelofibrosis; graft-versus-host disease; polycythemia vera; myeloproliferative disorders and belongs to the drug class multikinase inhibitors. Risk cannot be ruled out during pregnancy. Jakafi 25 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for INCY 25
Jakafi
- Generic Name
- ruxolitinib
- Imprint
- INCY 25
- Strength
- 25 mg
- Color
- White
- Shape
- Elliptical / Oval
- Availability
- Prescription only
- Drug Class
- Multikinase inhibitors
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Incyte Corporation
- National Drug Code (NDC)
- 50881-0025
More about Jakafi (ruxolitinib)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Compare Alternatives
- Pricing & Coupons
- En Español
- 15 Reviews
- Drug class: multikinase inhibitors
- FDA Approval History
Consumer resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.